Rising political tensions between the U.S. and China have prompted the FDA to implement stricter regulatory measures affecting Chinese-developed drug investments and clinical trials. The agency announced plans to review and potentially halt trials involving American cells sent to China and other designated countries for genetic engineering, citing biosecurity risks. This move signals a chilling effect on cross-border biotech collaborations and raises concerns over the future reach of Chinese therapeutics within U.S. markets.